Table 3 Baseline antithrombotic therapy and cardiovascular medications
Therapy and medications | CAD (n = 557) | No CAD (n = 2,904) | p-value |
|---|---|---|---|
Antiplatelet use, n (%) | 318 (57.1%) | 589 (20.3%) | < 0.001 |
Single antiplatelet | 245 (77.0%) | 560 (95.1%) | |
ASA | 195 (79.6%) | 506 (90.4%) | |
P2Y12 inhibitors | 50 (20.4%) | 54 (9.6%) | |
Dual antiplatelet | 73 (23.0%) | 26 (4.4%) | |
Oral anticoagulants, n (%) | 423 (75.9%) | 2,183 (75.2%) | 0.699 |
Warfarin | 385 (91.0%) | 1,991 (91.2%) | |
NOACs | 38 (9.0%) | 192 (8.8%) | |
Rate and rhythm control medications, n (%) | |||
Beta blocker | 430 (77.2%) | 1,994 (68.7%) | < 0.001 |
Diltiazem | 11 (2.0%) | 72 (2.5%) | 0.476 |
Verapamil | 4 (0.7%) | 29 (1.0%) | 0.533 |
Digoxin | 66 (11.8%) | 477 (16.4%) | 0.007 |
Amiodarone | 40 (7.2%) | 259 (8.9%) | 0.181 |
Other AAD | 5 (0.9%) | 79 (2.7%) | 0.010 |
Other medications, n (%) | |||
DHP-CCB | 130 (23.3%) | 727 (25.0%) | 0.396 |
PPI | 194 (34.8%) | 523 (18.0%) | < 0.001 |
Statin | 471 (84.6%) | 1,572 (54.1%) | < 0.001 |
ACEI | 158 (28.4%) | 616 (21.2%) | < 0.001 |
ARB | 172 (30.9%) | 648 (22.3%) | < 0.001 |